Recent Updates
Recently added Catalysts
SIBN Positive Sentiment Score: 70/100

SI-BONE To Present at Canaccord Genuity 44th Annual Growth Conference on August 14, 2024

Key Takeaway: SI-BONE, Inc. will present at the 2024 Canaccord Genuity 44th Annual Growth Conference in Boston on August 14, 2024. The company's management will host a fireside chat to engage with investors. SI-BONE is recognized as a leader in surgical treatment for sacropelvic disorders, with a history of supporting numerous procedures and extensive clinical evidence for its technologies.

Market Sentiment Analysis

POSITIVE FACTORS

  • Company is actively participating in a notable industry conference.
  • Management will be hosting a fireside chat, indicating engagement with investors.
  • SI-BONE has a strong track record with over 100,000 procedures performed.
  • The company has significant clinical evidence backing its technologies.

Full Press Release Details

SANTA CLARA, Calif., Aug. 06, 2024 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving sacropelvic disorders, today announced it will be participating in the upcoming 2024 Canaccord Genuity 44th Annual Growth Conference in Boston. Management will be hosting a fireside chat on Wednesday, August 14th, 2024, at 3:30 p.m. Eastern Time/ 1:30 p.m. Pacific Time.
Investors interested in listening to the conference call may do so by registering at this link: https://url.us.m.mimecastprotect.com/s/1f7GCNk84yt0E1qNsm3zxj?domain=wsw.com. Live audio of the webcast will be available on the “Investors” section of the company’s website at: www.si-bone.com. The webcast will be archived and available for replay for at least 90 days after the event.
SI-BONE (NASDAQ: SIBN) is a global leader in developing unique technologies for surgical treatment of sacropelvic disorders. Since pioneering minimally invasive SI joint surgery in 2009, SI-BONE has supported over 3,900 physicians in performing a total of over 100,000 procedures. A unique body of clinical evidence supports the use of SI-BONE’s technologies, including two randomized controlled trials and over 130 peer reviewed publications. SI-BONE has leveraged its leadership in minimally invasive SI joint fusion to commercialize novel solutions for adjacent markets, including adult deformity, spinopelvic fixation and pelvic trauma.
For additional information on the company or the products including risks and benefits, please visit www.si-bone.com.
Investor Contact: Saqib Iqbal investors@si-bone.com

Frequently Asked Questions

When is SI-BONE participating in the Canaccord Genuity conference?

SI-BONE will participate on August 14th, 2024, at 3:30 p.m. ET.

How can I listen to SI-BONE's conference call?

Register at the provided link or listen live on the company's website.

What is SI-BONE's focus in the medical device industry?

SI-BONE specializes in technologies for treating sacropelvic disorders.

How many procedures has SI-BONE supported?

SI-BONE has supported over 100,000 procedures since 2009.

Where can I find more information about SI-BONE?

Visit the company's website at www.si-bone.com for detailed information.

Last updated: Aug 6, 2024